Corporate Information – Page 9 – Alligator Bioscience

2023-05-26

Regulatory

Bulletin from the annual general meeting in Alligator Bioscience AB on 26 May 2023

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2023-05-18

Regulatory

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted O ...

2023-05-11

Regulatory

Orion selects lead antibodies from the first discovery program Collaboration aims to discover and develop new bispecific antibody cancer the ...

2023-04-282023-04-28

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-04-27

REACTIVE-2 is assessing the safety and immunological effect of mitazalimab in combination with MesoPher in metastatic pancreatic cancer Mita ...

2023-04-26

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2023-04-24

Regulatory

Today, on 24 April 2023, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows ...

2023-04-18

Presentation highlights potential of ATOR-4066 to induce strong anti-tumor responses in patients with CEACAM5-expressing tumors Data strongl ...

2023-04-12

OPTIMIZE-1 is assessing the safety and efficacy of mitazalimab in combination with mFOLFIRINOX in 1st line metastatic pancreatic cancer Inte ...